COVID-19 Myopericarditis in a Young Healthy Male

Matilde Bandeira1,2, Juliana Serrazina3, Carolina António Santos4, Nuno Jacinto4,6, António Pais de Lacerda4,5
1 Serviço de Reumatologia, Centro Hospitalar Universitário Lisboa Norte, Centro Académico de Medicina de Lisboa, Lisbon, Portugal
2 Unidade de Investigação em Reumatologia, Instituto de Medicina Molecular, Faculdade de Medicina da Universidade de Lisboa, Centro Académico de Medicina de Lisboa, Lisbon, Portugal
3 Serviço de Gastrenterologia e Hepatologia, Centro Hospitalar Universitário Lisboa Norte, Lisbon, Portugal
4 Serviço de Medicina II, Clínica Universitária Medicina II, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte, Lisbon, Portugal
5 Faculdade de Medicina da Universidade de Lisboa, Lisbon, Portugal
6 Critical Care Department, Hospital Professor Doutor Fernando da Fonseca, Amadora, Portugal

How to cite this article: Bandeira M, Serrazina J, Santos CA, Jacinto N, Pais de Lacerda A. COVID-19 myopericarditis in a young healthy male. EJCRIM 2022; 9:doi:10.12890/2022_003361.

Conflicts of Interests: The Authors declare that there are no competing interest
This article is licensed under a Commons Attribution Non-Commercial 4.0 License

ABSTRACT
SARS-CoV-2 infection can present in different clinical forms, most commonly as bilateral pneumonia, but also with pericardial/myocardial involvement. Cardiac involvement in COVID-19 is associated with worse outcomes.

The authors report a case of myopericarditis as the primary manifestation of SARS-CoV-2 infection in a 20-year-old male patient with no known cardiovascular (CV) disorders or risk factors.

The patient presented with pleuritic chest pain and high fever, with no respiratory symptoms. Electrocardiogram (ECG) and echocardiogram changes were consistent with pericarditis; concomitant elevation of cardiac enzymes revealed myocardial involvement. The patient had a slow but favourable evolution with no apparent impact on cardiac function. Other causes of myopericarditis were excluded and SARS-CoV-2 admitted as the most likely aetiological agent.

This case highlights possible cardiac involvement in SARS-CoV-2 infection with little or no pulmonary disease in a young healthy patient. Such systemic and potentially troublesome manifestations of COVID-19 are increasingly being described.

KEYWORDS
Myopericarditis, COVID-19, SARS-CoV-2

LEARNING POINTS
• Acute myopericarditis is a possible manifestation of SARS-CoV-2 infection.
• SARS-CoV-2 cardiac involvement may occur both in older and in younger previously healthy subjects, and could be more frequent than expected.
• Further investigation should address the prevalence of myocardium and pericardium involvement in COVID-19 patients, as well as its complications, sequelae and prognostic value for both older and young patients.

INTRODUCTION
Coronavirus disease 2019 (COVID-19) most frequently affects the lungs and can cause acute respiratory failure, although some patients are asymptomatic. SARS-CoV-2 binds to its receptor, angiotensin-converting-enzyme 2 (ACE2), which is highly expressed in the lungs, and also in the heart and kidneys1,2.
Myopericarditis is sometimes seen in clinical practice as acute pericarditis and myocarditis share similar aetiologies, in particular cardiotropic viruses[3]. Diagnosis usually relies on evidence of pericarditis associated with markers of myocardial injury. COVID-19-induced cardiac injury is a negative prognostic factor. The mechanisms responsible for cardiac involvement are not yet fully understood[4], but may include direct viral injury, systemic inflammation, plaque rupture or treatment side-effects[5, 6]. The absence of significant mononuclear infiltrates or other tissue lesions in histopathological reports suggests little direct viral involvement in myocardial injury[7].

CASE DESCRIPTION
A 20-year-old man presented to the emergency room with a 6-day history of myalgia, a high fever (39.5°C) and dysgeusia. His symptoms had recently worsened with retrosternal pain aggravated by inspiration. His previous medical history only included psoriasis, which was controlled with topical corticosteroids. A PCR test was positive for SARS-CoV-2. Laboratory tests on admission showed a leukocyte count of 11.61×10⁹ cells/l (4–11), neutrophils 8.37×10⁹ cells/l and lymphocytes 2.08×10⁹ cells/l, D-dimers 0.28 µg/ml (0–0.25) and elevated inflammatory parameters such as fibrinogen 770 mg/dl (200–400), ferritin 662 ng/ml (30–400) and C-reactive protein 28.3 mg/dl (<0.5), with an unremarkable chest x-ray. ECG showed PR-segment depressions on multiple leads (Fig. 1). Further blood work revealed troponin-T 144 ng/l (<14) and CK-MB 42.4 ng/ml (4.9–6.2), suggesting concomitant myocardial injury and the diagnosis of acute myopericarditis[8].

The patient was admitted to a COVID-19 ward. Pericardium hyperechogenicity and a small right atrium pericardial effusion on echocardiogram were consistent with acute pericarditis. Ibuprofen 600 mg three times a day and colchicine 0.5 mg once a day were added to his COVID-19 treatment protocol (lopinavir/ritonavir 400 mg/100 mg plus hydroxychloroquine 200 mg twice a day). Other common causes of myopericarditis were excluded, such as enteroviruses, herpesviruses, adenovirus and parvovirus. Bacterial cultures were negative as well as test results for Mycobacterium tuberculosis, Pneumococcus sp., Legionella pneumophila, Mycoplasma and Chlamydia pneumoniae. Toxoplasmosis, brucellosis, hepatitis B and C, syphilis, HIV and autoimmune causes were likewise excluded. The patient maintained high and frequent fever spikes, chest pain and elevated troponin-T rising to a maximum of 690 ng/l (<14) on day 4. Serial ECGs showed normalization of PR-segment depression and the presence of nearly-diffuse, concave-upwards ST-segment elevation (Fig. 2), consistent with pericarditis[9].

He later improved and was discharged asymptomatic after 10 days, with normal levels of cardiac enzymes and an echocardiogram showing pericardium thickening with no effusion. The ECG changes did not revert completely, showing a diffuse sustained ST-segment elevation.
Four weeks after admission, the patient underwent cardiac MRI (Fig. 3) which showed late subepicardial enhancement on the lateral-inferior and median wall, consistent with acute myocarditis with no effect on ventricular function (ejection fraction 63.2%). It also demonstrated a small pericardial effusion, with no signs of current inflammation. The patient showed normalization of ECG and echocardiogram changes after 6 months.
DISCUSSION
Uncommonly reported as manifestations of SARS-CoV-2 infection, myocardial and pericardial involvement should be considered by the healthcare professional when ECG abnormalities are seen in a COVID-19 patient [3]. The diagnosis of pericarditis was made as three out of four criteria were met; pericardial rub was missing. Myocardial involvement was evidenced by the significant elevation of myocardial enzymes [4]. Delayed MRI may be a limitation for detecting more typical findings. Pericarditis has been reported during the pandemic [10]. A recent systematic review included 34 patients with COVID-19 of whom 21 had concomitant myocardial involvement [11]. These patients were mostly male with a mean age of 53 years. Comorbidities were common, particularly hypertension, and the majority (63%) displayed abnormalities in lung parenchyma imaging. We describe significant cardiac involvement in a young healthy man with no history of cardiovascular disease who responded slowly to both non-steroidal anti-inflammatory drugs and colchicine. The patient reported no respiratory symptoms and there were no abnormalities on chest imaging, in contrast to most cases of myopericarditis reported in the literature.

In addition to conveying a higher mortality rate, underlying CV disease has also proved to be the most common comorbidity affecting patients hospitalized for COVID-19 [12]. Interestingly, patients with underlying CV disease with normal troponin had a better prognosis than patients without CV who showed elevated troponin levels [12]; however, CV involvement in COVID-19 is mainly reported in older patients with multiple comorbidities. Myocardial involvement in acute pericarditis with the classic aetiologies has no effect on prognosis [13]. However, in COVID-19, elevated troponin levels were correlated with more severe outcomes [4].

The imbalanced ACE/ACE2 ratio seen in psoriasis, with higher ACE tissue concentrations and activity as well as a tendency for higher ACE serum levels, correlates with higher CV comorbidity [13-15]. On the other hand, binding of the virus to ACE2 can result in ACE2 downregulation, which could lead to excessive production of angiotensin by the ACE enzyme, the opposing physiological homologue of ACE2. This apparent interaction between these two diseases could have made this particular COVID-19 patient more susceptible to cardiac involvement [14, 16].

CONCLUSION
This case highlights cardiac involvement in SARS-CoV-2 infection with no lung affects. Physicians should include COVID-19 in the differential diagnosis of patients presenting with myopericarditis. Prompt diagnosis and therapy may improve prognosis. Further studies should address the prevalence and prognostic relevance of cardiac involvement in young patients with COVID-19, who are usually expected to have a mild course of disease.

REFERENCES
1. Donoghue M, Hsieh F, Baronas E, Godbout K, Gosselin M, Stagliano N, et al. A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. Circ Res 2000;87(5):E1–9. doi:10.1161/01.RES.87.5.e1
2. Zou X, Chen K, Zou J, Han P, Hao J, Han Z. Single-cell RNA-seq data analysis on the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to 2019-nCoV infection. Front Med 2020;14(2):185–192. doi:10.3390/ijms8110276
3. Imazio M, Trinchero R. Myopericarditis: etiology, management, and prognosis. Int J Cardiol 2006;117(1):17–26. doi:10.1016/j.ijcard.2006.12.042
4. Shi S, Qin M, Shi B, Cai Y, Liu T, Yang F, et al. Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China. JAMA Cardiol 2020 Jul 1;5(7):802–810. doi:10.1001/jamacardio.2020.0950
5. Xiong T-Y, Redwood S, Prendergast B, Chen M. Coronaviruses and the cardiovascular system: acute and long-term implications. Eur Heart J 2020;41(19):1798–1800. doi:10.1093/eurheartj/ehaa231
6. Giustino G, Pinney SP, Lala A, Reddy VY, Johnston-Cox HA, Mechanick JI, et al. Coronavirus and cardiovascular disease, myocardial injury, and arrhythmia: JACC Focus Seminar. J Am Coll Cardiol 2020;76(17):2011–2023. doi:10.1016/j.jacc.2020.08.059
7. Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med 2020;8(4):420–422. doi:10.1016/S2213-2600(20)30076-X
8. Adler Y, Charron P, Imazio M, Badano L, Barón-Esquivias G, Bogaert J, et al. 2015 ESC Guidelines for the diagnosis and management of pericardial diseases: The Task Force for the Diagnosis and Management of Pericardial Diseases of the European Society of Cardiology (ESC) Endorsed by: The European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 2015;36(40):2921–2964. doi:10.1093/eurheartj/ehv318
9. Mani I. Electrocardiographic diagnosis of pericarditis. JAMA 2003;289(22):2942; author reply 2942–2943. doi:10.1001/jama.289.22.2942-a
10. Kumar R, Kumar J, Daly C, Edrosa SA. Acute pericarditis as a primary presentation of COVID-19. BMJ Case Rep 2020;13(8):e237617. doi:10.1136/bcr-2020-237617
11. Díaz-Arocútipa C, Saucedo-Chinchay J, Imazio M. Pericarditis in patients with COVID-19: a systematic review. J Cardiovasc Med (Hagerstown) 2021;22(9):693–700.
12. Guo T, Fan Y, Chen M, Wu X, Zhang L, He T, et al. Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19). JAMA Cardiol 2020 Jul 1;5(7):811–818. doi:10.1001/jamacardio.2020.1017
13. Imazio M, Demicheli B, Cecchi E, Belli R, Ghisio A, Bobbio M, et al. Cardiac troponin I in acute pericarditis. J Am Coll Cardiol 2003;42(12):2144–2148. doi:10.1016/j.jacc.2003.02.001
14. Bandeira M, Gil Á, Santos AC, Romão VC, Mascarenhas MR, Filipe P, et al. Angiotensin-converting enzyme activity may predict disease severity in psoriasis. Rheumatol 2020;2020;5:15–23. doi:10.3390/rheumatol20010001
15. AbdollahiMajd F, Niknejad N, Haghhighatkar HR, Namazi N, Niknejad N, Tabeli A. Angiotensin-converting enzyme and subclinical atherosclerosis in psoriasis: is there any association? A case-control study. J Acad Dermatol 2020;82(4):980–981.e1. doi:10.1016/j.jaad.2018.08.003
16. Shahidi-Dadras M, Tabary M, Robati RM, Araghi F, Dadkhahfar S. Psoriasis and risk of the COVID-19: is there a role for angiotensin converting enzyme (ACE)? J Dermatololg Treat 2022 Mar;33(2):1175–1176. doi:10.1080/09546634.2020.1782619